User:Mr. Ibrahem/Givosiran

Givosiran, sold under the brand name Givlaari, is a medication used to treat acute hepatic porphyria (AHP). It is given by injection under the skin. It is used in people over the age of 11.

Common side effects include pain at the site of injection, nausea, and tiredness. Other side effects may include anaphylaxis, kidney problems, and liver problems. It is a small interfering RNA (siRNA) that decreases the amount of the enzyme aminolevulinic acid synthase 1 (ALAS1) and therefore decreases the production of heme.

Givosiran was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom a 189 mg vial costs the NHS about £4200 as of 2021. This amount in the United States costs about 40,700 USD.